News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,658 Results
Type
Article (13469)
Company Profile (103)
Press Release (245086)
Section
Business (87793)
Career Advice (459)
Deals (15316)
Drug Delivery (60)
Drug Development (36452)
Employer Resources (49)
FDA (6228)
Job Trends (6178)
News (149681)
Policy (13988)
Tag
Academia (435)
Africa (312)
Alliances (23026)
Alzheimer's disease (321)
Approvals (6213)
Arizona (33)
Artificial intelligence (38)
Asia (19613)
Australia (2530)
Bankruptcy (143)
Best Places to Work (4182)
Biosimilars (31)
Biotechnology (41)
C2C Services and Suppliers (10602)
California (546)
Canada (413)
Cancer (109)
Career advice (401)
Cell therapy (22)
China (58)
Clinical research (29990)
Collaboration (43)
Connecticut (24)
COVID-19 (734)
Cystic fibrosis (21)
Data (64)
Diabetes (22)
Diagnostics (1196)
Drug pricing (47)
Earnings (31133)
Employer resources (43)
Europe (38346)
Events (36206)
Executive appointments (64)
FDA (6288)
Florida (68)
Funding (31)
Gene therapy (37)
GLP-1 (254)
Government (1247)
Healthcare (3497)
Hotbed/Location (177917)
Illinois (65)
Indiana (53)
Infectious disease (737)
Inflammatory bowel disease (40)
Interviews (57)
IPO (5775)
IRA (22)
Job creations (2046)
Job search strategy (371)
Kansas (48)
Layoffs (163)
Legal (3398)
Lung cancer (23)
Manufacturing (41)
Maryland (82)
Massachusetts (496)
Medical device (1251)
Medtech (1252)
Mergers & acquisitions (9468)
Metabolic disorders (90)
Minnesota (34)
Neuroscience (367)
New Jersey (224)
New York (144)
NextGen Class of 2024 (1575)
Non-profit (587)
North Carolina (220)
Northern California (242)
Obesity (56)
Ohio (28)
Opinion (104)
Patents (38)
Pennsylvania (178)
People (28192)
Pharmaceutical (58)
Phase I (7808)
Phase II (12683)
Phase III (11385)
Pipeline (46)
Podcasts (34)
Policy (33)
Postmarket research (1397)
Preclinical (3123)
Press Release (25)
Rare diseases (45)
Real estate (2624)
Regulatory (9685)
Research institute (561)
Resumes & cover letters (55)
South America (496)
Southern California (248)
Startups (1623)
Texas (66)
The Weekly (21)
United States (2462)
Vaccines (86)
Washington State (44)
Weight loss (47)
Date
Last 7 days (205)
Last 30 days (722)
Last 365 days (13333)
2024 (9014)
2023 (14244)
2022 (19556)
2021 (20068)
2020 (19033)
2019 (14886)
2018 (11713)
2017 (13890)
2016 (13130)
2015 (15472)
2014 (12420)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
258,658 Results for "tetraphase pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Fennec Pharmaceuticals Announces Management Change
Fennec Pharmaceuticals Inc., a commercial stage specialty pharmaceutical company, announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024.
July 1, 2024
·
4 min read
Deals
Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Deciphera Pharmaceuticals, Inc. today announced that it has entered into a definitive merger agreement with ONO Pharmaceutical Co., Ltd.
April 29, 2024
·
10 min read
BioMidwest
Aurorium Launches Haelium™ Pharmaceutical Solutions
Aurorium, a specialty ingredients manufacturer and materials innovation partner, is pleased to announce the launch of Haelium™ Pharmaceutical Solutions.
June 25, 2024
·
2 min read
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.
July 1, 2024
·
8 min read
Deals
Melinta Therapeutics Enters Into Agreement to Acquire Tetraphase Pharmaceuticals
Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant to which Melinta would acquire Tetraphase,
June 9, 2020
·
3 min read
Deals
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per Share
Cycle Pharmaceuticals Ltd today confirmed that it made a proposal to the Board of Directors of Vanda Pharmaceuticals, Inc. (“Vanda”) (NASDAQ: VNDA) on May 24, 2024 to acquire 100% of Vanda’s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million.
June 6, 2024
·
5 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
BioCapital
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces that it will expand its ongoing Netherton Syndrome clinical studies to include international sites.
June 27, 2024
·
4 min read
Press Releases
NLS Pharmaceutics Announces Registered Direct Offering
NLS Pharmaceutics Ltd. announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,277,750 of its common shares at a purchase price of $0.24 per share in a registered direct offering.
June 28, 2024
·
6 min read
Protect Pharmaceutical Corp. Issues Corporate Update
Protect Pharmaceutical Corp.'s (OTC: PRTT) (“Company”) President, Ali Yildiz, provides its shareholders with the following informational update: “July 1, 2024 Dear Shareholders: The Company’s PCAOB audit for the fiscal year of 2023 is near completion.
July 1, 2024
·
4 min read
1 of 25,866
Next